

Supplementary Figure S7

(A) Veliparib and talazoparib IC_{50} values from 7-day cell viability assays in control and BRCA1-reconstituted MDA-MB-436 cells. Error bars represent SEM of 2 independent experiments. (B) Lysates from DMSO (-), veliparib (2 μM) or talazoparib (5 nM) treated (72h) MDA-MB-436 control and BRCA1-reconstituted cells were analyzed by ELISA for cGAMP levels, which were expressed as fold change versus DMSO. Statistical analysis was performed using Kruskal-Wallis test with Dunn's post-hoc test. Error bars represent SEM of 2 independent experiments. (C-D) MDA-MB-436 control and BRCA1-reconstituted cells were treated with the indicated doses of talazoparib (T; nM) or veliparib (V; μM) and subjected to immunoblotting for pTBK1^{Ser172}, total TBK1 and STING, or qPCR for analysis of IFNβ, CCL5 and CXCL10 mRNA levels. Error bars represent SEM of 4 independent experiments. Statistical analyses were performed using Kruskal-Wallis test with Dunn's post-hoc test. (E) Murine K14 CRISPR/Cas9 control or STING KO cells were treated with increasing doses of the indicated PARP inhibitors for 7 days and subjected to cell viability assays to derive IC_{50} values. Error bars represent SEM of 3-4 independent experiments. Statistical analysis was performed using an unpaired *t*-test. (ns=not significant). Representative survival curves are shown on the right. Error bars on the curves represent SD from 3 technical replicates.